Molecular diagnostic laboratories are at the forefront of diagnostic advancements and deal with a diverse range of issues from complex reimbursement requirements, to how to properly handle their rapid growth, to how to best report and collaborate on test findings.
0%
XiFin LIS clients have successfully scaled their laboratory businesses by over 500% while on the system.
0%
As a proven leader in the molecular diagnostic testing market, XiFin RPM processes over 60% of all molecular testing claims nationwide, including those from small, high-growth molecular diagnostic companies as well as industry leaders like Myriad and Clarient.
0%
XiFin LIS has the ability to integrate with 90% of the top EMR systems while retaining historic data with no degradation of performance.
XiFin provides a comprehensive range of reimbursement and commercialization consulting services for molecular diagnostics.
We help early stage companies bring new molecular diagnostics and advanced diagnostic device concepts to market effectively, as well as guide mature companies on how to improve reimbursement processes to increase profitability. We also work with investors looking to inject capital in molecular diagnostics and medical device ventures with high potential.
Commercialization and Reimbursement Consulting offers flexibility to customize an engagement that addresses your needs and your budget. We can work with you on a specific need, such as developing a commercialization strategy, or we can work with you on an ongoing basis to ensure that our clients are always up to date on any issues that may impact their business, including market and regulatory changes. We help you stay ahead of change and ensure that you have the operational agility to handle rapid growth.
Complimentary Webinar
Breaking News on Trends and Denials Involving Lab Test Claims
Available On-Demand
Hosted By:
This white paper breaks down the many elements that go into crafting reimbursable and commercialized molecular diagnostics programs.
This paper proposes an alternative model for coverage determination that builds upon programs like MolDx by Palmetto and capitalizes on the knowledge gleaned from early registries, addresses the key underlying financial motivations that drive coverage determinations, and advocates for a shift to a Pay-For-Value model based on risk sharing between parties.
